Effects of bevacizmab, eribulin and oxaliplatin in relapsed patients with platinum-resistant and refractory ovarian carcinomas: A preliminary case series with biomarker evaluation.

person Jin Suminokura National Defense Medical College Hospital, Tokorozawa, Japan info_outline Jin Suminokura, Hiroko Kouta, Kazuya Kudoh, Miyuki Horikoshi, Tomoyuki Yoshikawa, Hiroko Matsuura, Morikazu Miyamoto, Masashi Takano, Yoshihiro Kikuchi

Authors person Jin Suminokura National Defense Medical College Hospital, Tokorozawa, Japan info_outline Jin Suminokura, Hiroko Kouta, Kazuya Kudoh, Miyuki Horikoshi, Tomoyuki Yoshikawa, Hiroko Matsuura, Morikazu Miyamoto, Masashi Takano, Yoshihiro Kikuchi Organizations National Defense Medical College Hospital, Tokorozawa, Japan, Ohki Memorial Kikuchi Cancer Center for Women, Tokorozawa, Japan, Tama-Hokubu Medical Center, Higashimurayama, Japan, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Japan, Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Japan, Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan Abstract Disclosures Research Funding Other Foundation Background: Eribulin is a candidate for paclitaxel-refractory breast cancers, and Bevacizmab (B) is known to enhance efficacy of anti-cancer agents in ovarian cancers. A combination therapy using weekly administration of B with eribulin and oxaliplatin (EriOX) in relapsed patients with platinum-resistant and refactory ovarian carcinomas (PR-ROC) was evaluated retrospectively, and the association with response and serum biomarkers was investigated. Methods: Medical charts of the patients who met the criteria shown below were identified: (a) histologically confirmed epithelial ovarian cancer (b) diagnosed as platinum-resistant ovarian cancer (c) treated with weekly-B-EriOX consisting of B (2mg/kg), eribulin (1mg/m 2 ), and oxaliplatin (30mg/m 2 ), three weeks on and one week off, q4weeks (d) written informed consent. Biomarker analyses including serum VEGF, BNP, p53, and IL-6 were also conducted. Results: A total of 34 patients were treated with weekly-B-EriOX. Median age of the patients was 58.5 years (range: 35-76), and median number of previous regimen was 4(range: 2-9). Overall, two patients (6%) had a complete response (CR), 8 patients (24%) had a partial remission (PR) and 16 patients (47%) had a stable disease (SD). The response rate and clinical benefit rate (CR+PR+SD) were 29% and 76%, respectively. Median progression-free survival was 4 months (range: 1-27+). Hematological adverse effects (AE) with grade 3/4 were observed in 4 patients (11%). Non-hematological AE greater than grade 2 was observed in one case: hypo albuminemia and edema, which were manageable and tolerable. The patients with elevation of serum mutated p53 protein and IL-6 had poorer prognosis. Conclusions: Weekly B and EriOX administration showed a remarkable response for patients with PR-ROC. Elevation of serum mutated p53 protein and IL-6 could be biomarkers for this regimen. These results warrant further prospective studies with additional biomarker analyses.